Navigation Links
Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Date:9/4/2008

Data Announcements Remain on Schedule with Two Abstracts Accepted for

Presentation, and Large Clinical Data Release in November 2008

BRIDGEWATER, N.J., Sept. 4 /PRNewswire/ -- Aegerion Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced the appointment of Peter L. Garrambone, Jr. to the Company's board of directors.

Peter Garrambone's career includes more than 50 pharmaceutical transactions executed during his 24-year tenure at Pfizer, where he was a senior vice president of Corporate Strategic Planning. At Pfizer, Mr. Garrambone led the company's corporate business development and strategic planning efforts. Most recently, Mr. Garrambone was senior vice president of Business Development for Reliant Pharmaceuticals, which was sold to GlaxoSmithKline for $1.65 billion in the fall of 2007.

"We are fortunate that Peter is joining the board of directors. His extensive strategic and licensing transaction expertise will be invaluable as the company continues the pursuit of its strategic plan with the availability of its important clinical data in November of this year," said David Scheer, Chairman and Co-Founder of Aegerion.

In furtherance of its strategic plan, the Company announced that it had secured additional funding from investors to support ongoing and future clinical trials. The Company will be presenting an abstract at both the American Association for the Study of Liver Disease and American Heart Association Meetings in the fourth quarter of 2008.

Aegerion anticipates receiving the results of three Phase II trials on AEGR 733 before the end of 2008. These trials, comprised of more than 460 patients, are designed to explore the efficacy, safety and tolerability of AEGR 733, Aegerion's lead compound. A Phase III study of AEGR 733 in the orphan population of homozygous familial hypercholesterolemic patients is currently underway.

In addition, Aegerion announced the transition of Jerry Wisler, Co- Founder, CEO and Director of Aegerion, who has left the Company to pursue personal interests.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The Company's primary focus is on hyperlipidemia. Its most advanced products have demonstrated significant LDL lowering activity in human trials and are currently in Phase III and Phase II testing.


'/>"/>
SOURCE Aegerion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
3. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... LONDON , December 9, 2016 ... ICD, Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac ... External Defibrillators, Wearable Cardioverter Defibrillators The ... grow at a CAGR of 5.3% from 2016-2020 ... is expected to grow at a CAGR of ...
(Date:12/9/2016)... Research and Markets has announced the addition of the "High ... offering. ... analyses the market by the following Technology Types: Label-Free Technology, Cell-Based Assay, ... Canada , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ...
(Date:12/9/2016)... Research and Markets has announced the ... 2021" report to their offering. ... Market growth can be ... the pharmaceutical and biotechnology industry and technological advancements like automation ... markets and growing research activities in toxicology and stem cells ...
Breaking Medicine Technology:
(Date:12/8/2016)... Tampa, FL (PRWEB) , ... December 08, 2016 ... ... been awarded accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), ... patients with advanced care and patient safety. Only a few hospitals and facilities ...
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc ... Language Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: ... , Results of the comparative usability study demonstrate that a dictation-based method (“NLP ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading ... has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE ... Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage Lung ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra ... weight loss and wellness program, at their world headquarters of Omni La Costa Resort ... long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it had joined the Pharmaceutical Supply Chain ... organization to unite pharmaceutical and healthcare companies that share a vision of better, ...
Breaking Medicine News(10 mins):